Autonomix reports positive preliminary PoC trial results in pancreatic cancer pain patients; 60% responders

Autonomix Medical, Inc.

60% of lead-in patients responded with mean 6.33 VAS pain reduction (8.0 to 1.67) at 7 days post-procedure.
No procedural complications or significant adverse events in the first five patients.
Responders reported 78% improvement in quality of health and 45% improvement in quality of life at 7 days.
Femoral access patients responded; brachial access did not; trial enrollment on track for year-end 2024.
Pain relief as quick as 1 day post-procedure; two patients succumbed to disease (expected, unrelated).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.